AU2015292956B2 - Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof - Google Patents

Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof Download PDF

Info

Publication number
AU2015292956B2
AU2015292956B2 AU2015292956A AU2015292956A AU2015292956B2 AU 2015292956 B2 AU2015292956 B2 AU 2015292956B2 AU 2015292956 A AU2015292956 A AU 2015292956A AU 2015292956 A AU2015292956 A AU 2015292956A AU 2015292956 B2 AU2015292956 B2 AU 2015292956B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
cytosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015292956A
Other languages
English (en)
Other versions
AU2015292956A1 (en
Inventor
Dong Ki Choi
Sung Hoon Kim
Yong Sung Kim
Seung Min Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orum Therapeutics Inc
Original Assignee
Orum Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orum Therapeutics Inc filed Critical Orum Therapeutics Inc
Priority claimed from PCT/KR2015/007627 external-priority patent/WO2016013871A1/ko
Publication of AU2015292956A1 publication Critical patent/AU2015292956A1/en
Application granted granted Critical
Publication of AU2015292956B2 publication Critical patent/AU2015292956B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
AU2015292956A 2014-07-22 2015-07-22 Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof Ceased AU2015292956B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20140092687 2014-07-22
KR10-2014-0092687 2014-07-22
KR1020150103214A KR101602876B1 (ko) 2014-07-22 2015-07-21 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR10-2015-0103214 2015-07-21
PCT/KR2015/007627 WO2016013871A1 (ko) 2014-07-22 2015-07-22 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용

Publications (2)

Publication Number Publication Date
AU2015292956A1 AU2015292956A1 (en) 2017-02-09
AU2015292956B2 true AU2015292956B2 (en) 2020-04-02

Family

ID=55354089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015292956A Ceased AU2015292956B2 (en) 2014-07-22 2015-07-22 Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof

Country Status (11)

Country Link
US (1) US10851177B2 (enExample)
EP (1) EP3173099B1 (enExample)
JP (1) JP6798988B2 (enExample)
KR (2) KR101602876B1 (enExample)
CN (1) CN106999575A (enExample)
AU (1) AU2015292956B2 (enExample)
BR (1) BR112017001306A2 (enExample)
CA (1) CA2955265A1 (enExample)
IL (1) IL250137B (enExample)
MX (1) MX2017001012A (enExample)
RU (1) RU2017103679A (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
JP2019520086A (ja) 2016-05-27 2019-07-18 オラム・セラピューティクス・インコーポレイテッド 細胞質浸透抗体およびその用途
WO2019107812A1 (ko) 2017-11-16 2019-06-06 오름테라퓨틱 주식회사 세포의 세포질에 침투하여 세포내 활성화된 ras를 억제하는 항체 및 이의 용도
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
JP2021532135A (ja) * 2018-07-23 2021-11-25 中外製薬株式会社 標的細胞特異的な細胞質侵入抗原結合分子
KR20200088780A (ko) * 2019-01-15 2020-07-23 오름테라퓨틱 주식회사 세포질 침투성이 증진된 항체
CN113825515A (zh) * 2019-05-01 2021-12-21 圣地亚哥德孔波斯特拉大学 调配成纳米胶囊的抗kras抗体的胞内递送
PE20231504A1 (es) * 2020-04-30 2023-09-26 Genentech Inc Anticuerpos especificos para kras y sus usos
IL307396A (en) * 2021-04-02 2023-12-01 Massachusetts Gen Hospital Methods for inhibiting RAS
KR102623211B1 (ko) 2021-07-20 2024-01-11 아주대학교산학협력단 세포 내부에 침투하여 표적단백질을 분해하여 제거하는 세포침투 분해항체 및 이의 용도
WO2023044432A2 (en) * 2021-09-17 2023-03-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeting mutant kras with a mutation specific iga

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
US20050288492A1 (en) * 2002-11-15 2005-12-29 Medical Research Council Anti-activated RAS antibodies
KR20100045683A (ko) * 2008-10-24 2010-05-04 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
US20140179543A1 (en) * 2011-03-03 2014-06-26 Isis Innovation Limited Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CN1241574A (zh) 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
KR100849941B1 (ko) 2008-04-29 2008-08-01 원우이에프엔지니어링주식회사 열 및 연기 화재감지장치 복합시험기
JP2011519370A (ja) 2008-04-30 2011-07-07 アジョウ・ユニヴァーシティ・インダストリー−アカデミック・コーオペレーション・ファンデーション 癌細胞の細胞死を誘導する抗核酸抗体及びこれを用いた癌予防または治療用組成物
CN101402675B (zh) 2008-11-28 2012-05-30 中国人民解放军第三军医大学第三附属医院 一种靶向抑制ανβ3阳性细胞增殖的环肽
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2012135831A1 (en) 2011-04-01 2012-10-04 Yale University Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US9815866B2 (en) 2012-09-14 2017-11-14 Japanese Foundation For Cancer Research Peptides that bind to epithelial cell adhesion molecule
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US20180208658A1 (en) 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
KR101790669B1 (ko) 2015-10-14 2017-10-26 아주대학교산학협력단 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도
JP2019520086A (ja) 2016-05-27 2019-07-18 オラム・セラピューティクス・インコーポレイテッド 細胞質浸透抗体およびその用途
KR101836392B1 (ko) 2016-08-17 2018-03-08 한림대학교 산학협력단 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물
WO2019107812A1 (ko) 2017-11-16 2019-06-06 오름테라퓨틱 주식회사 세포의 세포질에 침투하여 세포내 활성화된 ras를 억제하는 항체 및 이의 용도
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
US20050288492A1 (en) * 2002-11-15 2005-12-29 Medical Research Council Anti-activated RAS antibodies
KR20100045683A (ko) * 2008-10-24 2010-05-04 아주대학교산학협력단 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도
WO2010056043A2 (en) * 2008-11-11 2010-05-20 Ajou University Industry-Academic Cooperation Foundation Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
US20140179543A1 (en) * 2011-03-03 2014-06-26 Isis Innovation Limited Identification of small-molecule candidate therapeutics capable of inhibiting or interfering with a target protein-protein interaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA, T. et al., "Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation", EMBO J., (2003), vol. 22, no. 5, pages 1025 - 1035 *

Also Published As

Publication number Publication date
MX2017001012A (es) 2018-06-19
US20170158777A1 (en) 2017-06-08
RU2017103679A (ru) 2018-08-06
IL250137B (en) 2020-05-31
KR101732553B1 (ko) 2017-05-08
EP3173099A4 (en) 2018-03-14
KR20160033670A (ko) 2016-03-28
KR101602876B1 (ko) 2016-03-11
IL250137A0 (en) 2017-03-30
BR112017001306A2 (pt) 2018-01-30
CN106999575A (zh) 2017-08-01
AU2015292956A1 (en) 2017-02-09
JP2017529870A (ja) 2017-10-12
US10851177B2 (en) 2020-12-01
EP3173099B1 (en) 2020-03-04
EP3173099A1 (en) 2017-05-31
CA2955265A1 (en) 2016-01-28
JP6798988B2 (ja) 2020-12-09
KR20160011599A (ko) 2016-02-01

Similar Documents

Publication Publication Date Title
EP3173428B1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
AU2015292956B2 (en) Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
US20220298220A1 (en) Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused with Same, and Use Thereof
AU2017271189B2 (en) Cytosol-penetrating antibody and use thereof
KR102163305B1 (ko) 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도
KR102091195B1 (ko) 세포질 침투 항체 및 이의 용도
KR20180129514A (ko) 세포질 침투 항체 및 이의 용도
HK1240492A1 (en) Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
HK1240599A1 (en) Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
EP3466970A1 (en) Cytosol-penetrating antibody and use thereof
KR20250093184A (ko) 고효율 세포질 침투 능을 갖는 세포질 침투 항체 및 이의 용도
NZ749020B2 (en) Cytosol-penetrating antibody and use thereof
HK40008311A (en) Cytosol-penetrating antibody and use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHOD FOR INHIBITING INTRACELLULAR ACTIVATED RAS USING INTACT IMMUNOGLOBULIN-TYPE ANTIBODY HAVING CYTOSOL-PENETRATING ABILITY AND USE THEREOF

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired